Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Fludeoxyglucose
Generic Name
Fludeoxyglucose F18
Active Ingredient
Fludeoxyglucose F-18Category
Radioactive Diagnostic Agent [EPC]
Variants
6
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Fludeoxyglucose, you must consult a qualified healthcare professional.
| 300 mCi/mL | INJECTION | INTRAVENOUS | 60215-411 |
| 300 mCi/mL | INJECTION | INTRAVENOUS | 76326-001 |
| 400 mCi/mL | INJECTION | INTRAVENOUS | 13267-234 |
Detailed information about Fludeoxyglucose
Fludeoxyglucose F-18 is a radioactive diagnostic agent used in Positron Emission Tomography (PET) imaging to visualize glucose metabolism in oncology, cardiology, and neurology.
The standard adult dose of Fludeoxyglucose F-18 typically ranges from 5 to 10 mCi (185 to 370 MBq). The exact dose is calculated based on the patient's body weight, the specific type of PET scanner being used, and the clinical indication. For oncological and neurological imaging, the dose is usually administered as a single intravenous bolus injection. In cardiology, the dose is similar but may be administered following a 'glucose loading' protocol to ensure the heart muscle is actively using sugar at the time of the scan.
Fludeoxyglucose F-18 is approved for use in pediatric patients. The dosage for children is significantly lower than for adults and is strictly calculated based on body weight (typically 0.1 to 0.15 mCi per kilogram of body weight). The goal in pediatric imaging is to use the 'ALARA' principle (As Low As Reasonably Achievable) to minimize radiation exposure while still obtaining a clear diagnostic image. Healthcare providers use specialized pediatric dosing charts to ensure safety.
Because Fludeoxyglucose F-18 is primarily excreted through the kidneys, patients with renal impairment (kidney disease) require special consideration. While the dose itself might not always be reduced, the radiation stays in the body longer if the kidneys cannot flush it out. These patients are often encouraged to drink extra fluids and void (urinate) frequently after the procedure to reduce the radiation dose to the bladder.
No specific dosage adjustments are required for patients with hepatic (liver) impairment, as the liver does not play a major role in the elimination of this tracer.
In elderly patients, no specific dose adjustments are typically required based on age alone. However, clinicians must account for the higher likelihood of reduced kidney function and pre-existing conditions like diabetes, which can interfere with the scan results.
Fludeoxyglucose F-18 is administered only by trained nuclear medicine professionals in a clinical setting. However, the patient has several critical responsibilities to ensure the 'medication' works correctly:
Since Fludeoxyglucose F-18 is administered for a scheduled diagnostic procedure, a 'missed dose' in the traditional sense is not possible. However, if a patient is late for their appointment, the dose may 'decay' (lose its radioactivity) to the point where it is no longer useful. In such cases, the procedure must be rescheduled, and a new dose must be ordered from the radiopharmacy.
An overdose of Fludeoxyglucose F-18 is extremely rare due to the strict controls in nuclear medicine. If an excessive dose were given, the primary concern would be increased radiation exposure. The treatment for an overdose involves 'forced diuresis'—encouraging the patient to drink large amounts of fluids and urinate frequently to flush the tracer out of the system as quickly as possible. Emergency measures for radiation toxicity are generally not required for the doses used in PET imaging.
> Important: Follow your healthcare provider's dosing instructions and pre-scan preparations carefully. Failure to fast or rest properly can result in an inaccurate scan and the need for a repeat procedure.
Fludeoxyglucose F-18 is generally very well tolerated, and most patients experience no side effects at all. Because it is a glucose analog and administered in such tiny chemical amounts (nanograms), it does not produce the 'drug effects' associated with traditional medications. However, the most common 'side effect' is actually related to the administration process:
Fludeoxyglucose F-18 is a radioactive material and must be handled with specialized safety precautions. Patients should be aware that for a few hours after the injection, they will be emitting a small amount of radiation. While this is not considered dangerous to the general public, most clinics recommend avoiding prolonged close contact with pregnant women or small infants for about 12 hours after the scan.
No FDA black box warnings for Fludeoxyglucose F-18.
There are no medications that are 'contraindicated' in the sense that they will cause a toxic chemical reaction with Fludeoxyglucose F-18. However, certain drugs can make the PET scan medically useless by interfering with glucose distribution.
There are very few absolute contraindications for Fludeoxyglucose F-18 because it is a diagnostic tool used in life-threatening situations. However, the following apply:
Relative contraindications require a 'risk-benefit' analysis by the physician:
Fludeoxyglucose F-18 is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether FDG can cause fetal harm. However, it is well-established that ionizing radiation is potentially harmful to a developing fetus. The risk is highest during the period of organogenesis (first trimester). If a PET scan is absolutely necessary for a pregnant woman (e.g., for aggressive lymphoma), the dose may be minimized, and the patient is encouraged to hydrate and void frequently to move the radiation away from the pelvic area.
Fludeoxyglucose F-18 is excreted in human breast milk. To minimize the risk of radiation exposure to the nursing infant, a 'pump and dump' period is recommended. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) typically suggests interrupting breastfeeding for at least 12 hours after the injection. During this time, milk should be expressed and discarded. By 12 hours, more than 98% of the radioactivity will have decayed.
Fludeoxyglucose F-18 is a glucose analog. It is transported into cells by GLUT-1 and GLUT-3 transporters. Once intracellular, it is phosphorylated by the enzyme hexokinase (specifically Hexokinase II in many tumors) into 18F-FDG-6-phosphate. Because the 2-carbon hydroxyl group of glucose has been replaced by a Fluorine-18 atom, the molecule cannot undergo further glycolysis or be converted into glycogen. It is also a poor substrate for glucose-6-phosphatase, the enzyme that would normally allow it to exit the cell. This results in 'metabolic trapping,' where the radioactivity accumulates in proportion to the cell's rate of glucose consumption.
Fludeoxyglucose F-18 has no significant pharmacodynamic effects at the doses used for imaging. It does not alter blood pressure, heart rate, or blood glucose levels. Its only 'effect' is the emission of radiation. The time to onset for optimal imaging is 30–60 minutes, which is the time required for the tracer to accumulate in target tissues and clear from the background blood pool. The duration of the 'effect' is limited by the 110-minute physical half-life of the isotope.
Common questions about Fludeoxyglucose
Fludeoxyglucose F-18 is primarily used as a diagnostic tracer in PET scans to visualize glucose metabolism in the body. In oncology, it helps doctors detect cancer, determine if it has spread, and see if treatments are working. In neurology, it is used to identify areas of the brain causing seizures and to help diagnose types of dementia like Alzheimer's. In cardiology, it helps identify living heart muscle that could benefit from surgery. Because it mimics sugar, it 'lights up' areas with high energy use, which are often sites of disease.
Side effects from Fludeoxyglucose F-18 are extremely rare because it is a glucose analog given in a very small amount. Some patients may experience minor discomfort or a cold sensation at the injection site. Occasionally, patients report a mild headache or dizziness, though these are often related to the required fasting rather than the drug itself. Allergic reactions are possible but occur in fewer than 1 in 1,000 patients. Most people feel completely normal during and after the administration.
You should avoid alcohol for at least 24 hours before receiving Fludeoxyglucose F-18. Alcohol can significantly alter your blood sugar levels and your body's metabolic state, which can lead to an inaccurate or unreadable PET scan. While there is no dangerous chemical reaction between the tracer and alcohol, the goal is to have your metabolism in a 'steady state.' After the scan is finished and you have eaten a meal, there is generally no restriction on alcohol, though you should check with your doctor first.
Fludeoxyglucose F-18 is generally avoided during pregnancy unless the diagnostic benefit clearly outweighs the risk to the fetus. It is a radioactive agent, and ionizing radiation can potentially interfere with fetal development. If you are pregnant or think you might be, you must inform your doctor before the scan. In some cases, alternative imaging like MRI or ultrasound may be used. If the scan must be done, special precautions are taken to minimize the radiation dose reaching the pelvic area.
After the Fludeoxyglucose F-18 is injected into your vein, it takes approximately 30 to 60 minutes for the tracer to circulate and accumulate in your tissues. This is known as the 'uptake period.' During this time, you will be asked to sit or lie quietly so the tracer doesn't go into your muscles. The PET scan itself usually begins about an hour after the injection. The radioactivity decays quickly, with a half-life of 110 minutes, meaning most of it is gone from your body within 12 hours.
Yes, because Fludeoxyglucose F-18 is a one-time diagnostic injection, there is no need to 'stop' taking it. It is not a daily medication and does not stay in your system long-term. There are no withdrawal symptoms or physical dependencies associated with this agent. Once the scan is over, the drug naturally leaves your body through your urine and radioactive decay. You do not need to follow any special tapering schedule after your procedure is complete.
If you miss your appointment for a Fludeoxyglucose F-18 injection, you must contact the imaging center immediately to reschedule. Because the drug is radioactive and has a very short half-life of 110 minutes, it 'expires' very quickly after it is produced. A dose ordered for a 9:00 AM appointment will be too weak to use by 11:00 AM. You cannot 'make up' the dose at home; it must be administered by a professional in a clinical setting with a freshly prepared batch.
No, Fludeoxyglucose F-18 does not cause weight gain. Although it is a sugar-based molecule, the actual amount of 'sugar' in the injection is less than a tiny fraction of a single grain of table sugar. It has no caloric value and does not affect your metabolism in a way that would lead to weight changes. Any weight changes you experience would be related to your underlying medical condition or other medications you may be taking, not the PET scan tracer.
Fludeoxyglucose F-18 can be used while taking most medications, but some drugs like insulin and steroids must be carefully timed. Insulin can drive the tracer into your muscles instead of where the doctor needs to look, and steroids can raise your blood sugar, making the scan less effective. You should provide your healthcare team with a full list of your medications, especially for diabetes or inflammation. They will give you specific instructions on which ones to take or skip on the morning of your scan.
Fludeoxyglucose F-18 is a generic name for the radiopharmaceutical, and it is produced by many different specialized radiopharmacies. It does not have a single 'brand name' in the way that drugs like Tylenol or Lipitor do. Because it must be made fresh daily in a cyclotron, it is supplied to hospitals as 'Fludeoxyglucose F 18 Injection.' There is no difference in quality between different suppliers, as all must meet strict FDA standards for purity and radioactivity levels.
Other drugs with the same active ingredient (Fludeoxyglucose F-18)
While Fludeoxyglucose F-18 is exceptionally safe, any medical procedure involving an injection carries a minute risk of serious reactions.
> Warning: Stop taking Fludeoxyglucose F-18 (inform your technician) and call your doctor immediately if you experience any of these:
The primary long-term concern with any radiopharmaceutical is the cumulative risk of radiation-induced cancer. Every PET scan contributes a small amount of ionizing radiation to the patient's lifetime total. For a standard FDG-PET scan, the effective radiation dose is approximately 7 to 8 millisieverts (mSv), which is roughly equivalent to the amount of natural background radiation a person receives over 2 to 3 years. While the risk from a single scan is very low, multiple scans over many years increase the theoretical risk of developing a secondary malignancy. Healthcare providers always weigh this theoretical long-term risk against the immediate need to diagnose or treat a life-threatening disease like cancer.
As of 2026, the FDA has not issued any Black Box Warnings for Fludeoxyglucose F-18. It is considered one of the safest diagnostic agents in modern medicine when used according to established protocols.
Report any unusual symptoms to your healthcare provider or the nuclear medicine staff immediately following your injection.
Fludeoxyglucose F-18 does not cause sedation or cognitive impairment. However, the fasting required for the scan can make some patients feel lightheaded or weak. If you feel faint due to lack of food, you should not drive until you have eaten a meal and feel stable. Most patients can drive themselves home immediately after the procedure.
There is no direct chemical interaction between Fludeoxyglucose F-18 and alcohol. However, alcohol consumption can significantly alter blood sugar levels and liver metabolism. Patients are strictly advised to avoid alcohol for at least 24 hours before their PET scan to ensure the metabolic data collected is accurate.
Fludeoxyglucose F-18 is a single-use diagnostic agent. There are no tapering requirements or withdrawal syndromes. Once the procedure is complete and the radiation has decayed (within 24 hours), the drug is gone from the system.
> Important: Discuss all your medical conditions, especially diabetes and kidney disease, with your healthcare provider before starting Fludeoxyglucose F-18.
For each major interaction, the mechanism is usually pharmacodynamic (changing how the body handles glucose) rather than pharmacokinetic (changing how the drug is broken down). The clinical consequence is a 'non-diagnostic' or 'false' scan result. Management always involves careful timing of medications around the scan appointment.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for diabetes or inflammation.
There is no known cross-sensitivity between Fludeoxyglucose F-18 and iodinated contrast media (used in CT scans) or gadolinium (used in MRI). Patients allergic to 'CT dye' can safely receive Fludeoxyglucose F-18, as they are chemically unrelated.
> Important: Your healthcare provider will evaluate your complete medical history and current metabolic state before prescribing Fludeoxyglucose F-18.
Clinical studies have not identified significant differences in safety or effectiveness between elderly and younger patients. However, the elderly are more likely to have reduced renal function. Since the tracer is cleared through the urine, elderly patients should be monitored for adequate hydration. There is no increased 'fall risk' directly from the drug, but the required fasting may cause orthostatic hypotension (dizziness upon standing) in older adults.
In patients with renal impairment, the physical half-life of the tracer remains 110 minutes, but the biological clearance is delayed. This results in a higher radiation dose to the kidneys and bladder. No specific dose reduction is mandated, but the 'ALARA' principle is applied, and post-scan hydration is critical. For patients on dialysis, the scan should ideally be performed on a day when dialysis is scheduled shortly after the procedure to help clear the tracer.
No dosage adjustments are needed for patients with liver disease. The liver's metabolic capacity does not affect the 'metabolic trapping' mechanism of FDG-6-phosphate.
> Important: Special populations require individualized medical assessment. Always inform the imaging staff if you are pregnant, nursing, or have kidney disease.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | Negligible |
| Physical Half-life | 109.8 minutes |
| Biological Half-life | ~2 hours (Renal) |
| Tmax (Uptake) | 30 - 90 minutes |
| Metabolism | Phosphorylation (not CYP) |
| Excretion | Renal (20% in 2 hours) |
Fludeoxyglucose F-18 is classified as a Radioactive Diagnostic Agent and a Radiopharmaceutical. It is the 'gold standard' tracer for Positron Emission Tomography (PET). Related medications include other F-18 labeled tracers like Florbetapir (for amyloid plaques) or Fluciclovine (for prostate cancer), though FDG remains the most widely used due to its broad application in oncology.